The Race To The Bottom In The Chinese Pharmaceutical Market Reinforces The Need To Market In The United States

while new drugs may be approved in China, unless they have unique mechanisms of action, they may simply join a race to the bottom in terms of domestic reimbursement. Hence the increasing trend for Chi...